Ardelyx (ARDX) Current Deferred Revenue (2013 - 2026)
Ardelyx posted quarterly Current Deferred Revenue of $3.2 million for Q1 2026, down 70.24% year-on-year from $10.9 million in Q1 2025, and up 169.32% on a QoQ basis from $1.2 million in Q4 2025.
Ardelyx (ARDX) has 12 years of Current Deferred Revenue data on file, last reported at $3.2 million in Q1 2026.
- For the quarter ending Q1 2026, Current Deferred Revenue fell 70.24% year-over-year to $3.2 million; the trailing twelve-month figure through Mar 2026 stood at $3.2 million (down 70.24% YoY), and the FY2025 full-year result was $1.2 million, down 88.71% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $3.2 million, up from $1.2 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $10.9 million in Q1 2025 and bottomed at $1.2 million in Q4 2025.
- The 5-year median for Current Deferred Revenue is $6.4 million (2025), against an average of $6.5 million.
- The widest annual swing landed in 2022, when Current Deferred Revenue jumped 659.58%; it then sank 88.71% in 2025.
- A 5-year view of Current Deferred Revenue shows it stood at $4.2 million in 2022, then soared by 70.55% to $7.2 million in 2023, then jumped by 48.79% to $10.7 million in 2024, then tumbled by 88.71% to $1.2 million in 2025, then soared by 169.32% to $3.2 million in 2026.
- The last three Current Deferred Revenue figures came in at $3.2 million (Q1 2026), $1.2 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Ardelyx | 1.48 Bn | 1.25 Bn | 89.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.25 Mn |
| Dec 31, 2025 | 1.21 Mn |
| Sep 30, 2025 | 6.58 Mn |
| Jun 30, 2025 | 6.28 Mn |
| Mar 31, 2025 | 10.91 Mn |
| Dec 31, 2024 | 10.69 Mn |
| Sep 30, 2024 | 7.27 Mn |
| Jun 30, 2024 | 10.83 Mn |
| Mar 31, 2024 | 6.59 Mn |
| Dec 31, 2023 | 7.18 Mn |
| Sep 30, 2023 | 4.07 Mn |
| Jun 30, 2023 | 5.96 Mn |
| Mar 31, 2023 | 5.55 Mn |
| Dec 31, 2022 | 4.21 Mn |
| Sep 30, 2022 | 4.00 Mn |
| Jun 30, 2022 | 10.00 Mn |
| Sep 30, 2021 | 527,000.00 |
| Jun 30, 2021 | 1.41 Mn |
| Mar 31, 2021 | 2.72 Mn |
| Dec 31, 2020 | 4.18 Mn |
| Sep 30, 2020 | 885,000.00 |
| Jun 30, 2020 | 2.24 Mn |
| Mar 31, 2020 | 3.37 Mn |
| Dec 31, 2019 | 4.54 Mn |
| Jun 30, 2019 | 1.00 Mn |
| Mar 31, 2019 | 1.00 Mn |
| Dec 31, 2018 | 1.00 Mn |
| Sep 30, 2018 | 1.00 Mn |
| Jun 30, 2018 | 1.00 Mn |
| Mar 31, 2018 | 2.30 Mn |
| Mar 31, 2015 | 15.95 Mn |
| Dec 31, 2014 | 15.98 Mn |
| Sep 30, 2014 | 16.48 Mn |
| Jun 30, 2014 | 23.22 Mn |
| Dec 31, 2013 | 13.83 Mn |